You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
|
|---|---|
| Published in |
Clinical Cancer Research, May 2022
|
| DOI | 10.1158/1078-0432.ccr-22-0061 |
| Pubmed ID | |
| Authors |
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C Fan, Benjamin A Gartrell, Oscar B Goodman, Petros G Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M Tannir |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 47% |
| Argentina | 1 | 7% |
| United Kingdom | 1 | 7% |
| France | 1 | 7% |
| Unknown | 5 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 47% |
| Scientists | 6 | 40% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 15% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Unspecified | 1 | 4% |
| Other | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 15 | 56% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Medicine and Dentistry | 3 | 11% |
| Unspecified | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 15 | 56% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2022.
All research outputs
#1,020,259
of 24,394,820 outputs
Outputs from Clinical Cancer Research
#689
of 13,000 outputs
Outputs of similar age
#24,373
of 432,611 outputs
Outputs of similar age from Clinical Cancer Research
#15
of 138 outputs
Altmetric has tracked 24,394,820 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,000 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 432,611 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.